Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.075
EU - Europa 4.327
AS - Asia 1.611
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 10
OC - Oceania 8
Totale 14.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.956
IT - Italia 1.166
DE - Germania 763
CN - Cina 641
IE - Irlanda 637
SG - Singapore 538
SE - Svezia 532
RU - Federazione Russa 364
UA - Ucraina 268
GB - Regno Unito 195
HK - Hong Kong 194
CA - Canada 118
FI - Finlandia 97
IN - India 77
PL - Polonia 73
FR - Francia 63
BE - Belgio 54
VN - Vietnam 47
TR - Turchia 42
DK - Danimarca 36
ID - Indonesia 26
NL - Olanda 22
IR - Iran 15
EU - Europa 14
ES - Italia 13
KR - Corea 10
JP - Giappone 9
AU - Australia 8
PE - Perù 7
BR - Brasile 6
CZ - Repubblica Ceca 6
EG - Egitto 5
RO - Romania 5
AT - Austria 4
BG - Bulgaria 4
CL - Cile 4
MK - Macedonia 4
NO - Norvegia 4
CH - Svizzera 3
MY - Malesia 3
BY - Bielorussia 2
GR - Grecia 2
LT - Lituania 2
MU - Mauritius 2
PT - Portogallo 2
SC - Seychelles 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
EE - Estonia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
PR - Porto Rico 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
YE - Yemen 1
Totale 14.064
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.939
Woodbridge 726
Fairfield 689
Dublin 627
Chandler 602
Frankfurt am Main 590
Milan 466
Wilmington 444
Singapore 416
Houston 409
Ashburn 379
Jacksonville 267
Seattle 253
Cambridge 247
Dearborn 247
New York 238
Hong Kong 193
Princeton 172
Nanjing 124
Shanghai 118
Santa Clara 92
Altamura 83
Lawrence 79
Beijing 70
Lodz 70
Brussels 52
San Diego 47
Helsinki 46
Lachine 44
Boardman 41
Fremont 38
Lissone 36
Shenyang 33
Nanchang 32
Andover 31
Guangzhou 30
Los Angeles 30
Romola 29
Ottawa 28
Göttingen 27
Jakarta 26
Munich 25
Rome 24
Toronto 23
Carate Brianza 21
Falls Church 21
Jiaxing 21
Hebei 20
Jinan 20
Mountain View 19
Norwalk 19
Chicago 18
Kunming 18
Kocaeli 17
Pune 17
Dong Ket 16
Edmonton 16
Hangzhou 16
Monza 16
Tianjin 16
London 15
Redmond 13
Changsha 12
Desio 12
Kiev 11
Taizhou 11
Turin 11
Bari 10
Cesano Maderno 10
Genoa 10
Zhengzhou 10
Bonndorf 9
Cinisello Balsamo 9
Fürstenwalde 9
Sesto San Giovanni 9
Hefei 8
Washington 8
Changchun 7
Daejeon 7
Huizen 7
Mumbai 7
Riva del Garda 7
Boston 6
Detroit 6
Duncan 6
Kilburn 6
Lanzhou 6
Lima 6
Lleida 6
Meda 6
Ningbo 6
Phoenix 6
Como 5
Delhi 5
Lappeenranta 5
Pavia 5
San Mateo 5
Taku 5
Trento 5
Verona 5
Totale 10.785
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 352
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 314
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 285
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 275
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 267
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 261
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 258
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 251
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 240
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 221
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 217
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 213
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 207
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 198
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 197
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 196
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 196
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 194
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 193
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 188
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 188
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 186
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 185
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 185
Inhibition of RET tyrosine kinase by SU5416 184
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 181
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 181
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 181
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 181
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 176
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 175
Expression, purification, and inhibition of human RET tyrosine kinase 175
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 170
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 169
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 167
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 165
We shall overcome (drug resistance) some day 165
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 164
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 162
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 160
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 160
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 156
Dual kinase targeting in leukemia 156
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 154
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 153
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 150
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 148
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 148
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 146
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer 143
Novel targeted therapeutics for MEN2 137
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 137
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 136
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 134
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 132
Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl 130
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 123
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 123
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 123
Anaplastic Lymphoma kinase assay, reagents and composition thereof 119
New developments in the treatment of ALK-driven malignancies 116
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 114
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 114
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 113
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 112
RET kinase inhibitors: a review of recent patents (2012–2015) 109
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 109
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 107
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 107
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 103
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells 98
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 97
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 96
Expanding the portfolio of anti-ALK weapons 95
Characterization of mouse myotilin and its promoter 95
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 95
Role of TMPRSS2/ERG in cellular transformation 91
Targeting drug resistance mutations: Discovery of EUD-GK-91 chemical series 91
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead 89
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 88
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 86
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 86
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 85
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 83
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 82
Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells 78
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 77
Development of RET kinase inhibitors for targeted cancer therapy 75
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 74
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 73
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 67
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 63
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 63
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 63
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 62
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 58
Inhibitors of the anaplastic lymphoma kinase 55
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 53
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 53
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 48
Totale 14.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.959 0 0 0 208 233 286 396 208 237 171 159 61
2020/20212.141 93 107 204 252 168 208 179 214 187 204 151 174
2021/20221.316 112 154 136 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20251.261 275 476 319 191 0 0 0 0 0 0 0 0
Totale 14.713